AIDS vaccine advisory committee
Executive Summary
An ongoing Phase III study of Aventis-Pasteur's ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX will be discussed at FDA's Vaccines & Related Biologics Advisory Committee's Sept. 23 meeting. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 9 a.m. The committee will be closed from 11 a.m. to 12:15 p.m. to discuss trade secret/confidential information [Editor's Note: To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.